Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells-Reference-Cited by-同舟云学术

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells

Published:2021-10-13 Issue:1 Volume:21 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Zhang Ying,Liu Qiuzi,Wei Wei,Zhang Guoan,Yan Siyuan,Dai Rongrong,Sun Ying,Su Dubo,Lv Shun,Xia Yong,Li Jing,Li Changlin

Abstract

Abstract Background Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown. Methods Anticancer effects of combination of BZM and MTX were determined by apoptosis and proliferation assay in vivo and in vitro. Expression of β-Catenin and its target genes were characterized by western blot and Real-time PCR. Results BZM significantly enhanced MTX-induced antiproliferation in vivo and in vitro. Mice administered a combination of BZM and MTX displayed attenuated tumor growth and prolonged survival. BZM significantly attenuated MTX-induced apoptosis. Moreover, the combination of BZM and MTX contributed to inhibition of the Wnt/β-Catenin signaling pathway compared to monotherapy. Conclusions This study demonstrates that BZM enhances MTX-induced anti-tumor effects by inhibiting the Wnt/β-Catenin signaling pathway in prostate cancer cells.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

https://link.springer.com/content/pdf/10.1186/s12885-021-08841-1.pdf

Reference48 articles.

1. Nayak L, Bhattacharyya NP, De RK. Wnt signal transduction pathways: modules, development and evolution. BMC Syst Biol. 2016;10(Suppl 2):44.

2. Croce JC, McClay DR. Evolution of the Wnt pathways. Methods Mol Biol. 2008;469:3–18. https://doi.org/10.1007/978-1-60327-469-2_1.

3. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32. https://doi.org/10.1053/j.gastro.2011.12.001.

4. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24(3):245–50. https://doi.org/10.1038/73448.

5. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275(5307):1790–2. https://doi.org/10.1126/science.275.5307.1790.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A subcomponent-guided deep learning method for interpretable cancer drug response prediction;PLOS Computational Biology;2023-08-21

2. Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence;Expert Opinion on Therapeutic Targets;2023-08-03

3. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells;Medical Oncology;2023-06-01

4. Macromolecular NO‐Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer;Advanced Healthcare Materials;2022-12-04

5. Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development;International Journal of Molecular Sciences;2022-02-23